NCT06792422View on ClinicalTrials.gov

A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

PHASE4RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

December 31, 2028

Conditions
Primary Open Angle Glaucoma (POAG)Open-Angle GlaucomaGlaucoma
Interventions
DRUG

Oral semaglutide

"Participants will receive oral semaglutide once daily.~1. Starting dose 3 mg/day for one month (day 1-28)~2. Intermediate dose 7 mg/day for one month (day 29-56)~3. Maintenance dose 14 mg/day (day 57-182)"

DRUG

Placebo

"Participants will receive an oral placebo once daily.~1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28)~2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56)~3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)"

Trial Locations (1)

2600

RECRUITING

Department of Ophthalmology, Rigshospitalet, Glostrup Municipality

All Listed Sponsors
lead

Glostrup University Hospital, Copenhagen

OTHER